Advances in Therapeutic Strategies for Type 2 Diabetes Mellitus: Emphasis on Alpha-Glucosidase Inhibitors and In Silico approaches

Arya Vinay [1], Ajay Kumar[1, *]

[1]Department of Biotechnology, Faculty of Engineering & Technology, Rama University, Kanpur, India

Corresponding email:

* Dr. Ajay Kumar ,

Department of Biotechnology, Faculty of Engineering & Technology, Rama University, Kanpur, India

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial and progressive metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and pancreatic beta-cell dysfunction. The global burden of T2DM is increasing at an alarming rate, with significant health and economic implications. Current treatment options, although effective to some extent, are often associated with adverse effects, diminishing efficacy over time, and inability to halt disease progression. One therapeutic target gaining increasing attention is intestinal alpha-glucosidase, an enzyme involved in carbohydrate digestion. Alpha-glucosidase inhibitors (AGIs) help modulate postprandial glucose spikes by delaying the breakdown and absorption of carbohydrates. The integration of computational or in silico approaches in the early stages of drug discovery has revolutionized the search for new AGIs. This review provides a comprehensive overview of the pathophysiology of T2DM, current treatment modalities, the pharmacological role of AGIs, and recent advances in in silico drug discovery techniques aimed at identifying novel AGIs.

Keywords- Type 2 diabetes mellitus, hyperglycemia, Alpha-glucosidase inhibitors, in silico

1. Introduction

Diabetes mellitus is one of the most prevalent and pressing chronic health conditions affecting populations worldwide. It represents a spectrum of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Among the various types of diabetes, Type 2 diabetes mellitus (T2DM) is the most common form, accounting for approximately 90 to 95 percent of all diagnosed cases. T2DM typically develops in adulthood, although its incidence is increasingly seen among younger age groups due to changing lifestyles, poor dietary habits, sedentary behavior, and rising obesity rates. T2DM is fundamentally a multifactorial disease caused by a complex interplay between genetic predisposition and environmental factors. The pathophysiology of T2DM primarily involves two critical abnormalities: insulin resistance in peripheral tissues such as skeletal muscle, liver, and adipose tissue, and progressive dysfunction of pancreatic beta-cells, which are responsible for insulin production. In the early stages of the disease, the pancreas compensates for insulin resistance by increasing insulin secretion. However, over time, this compensatory mechanism fails, and insulin production declines, leading to sustained elevations in blood glucose levels—clinically referred to as chronic hyperglycemia. The hyperglycemic state in T2DM is insidious and often goes undiagnosed for several years, during which significant metabolic and vascular damage may occur. Persistent high blood glucose levels exert toxic effects on various organ systems (DeFronzo and R.A 2009). These effects manifest as a wide range of microvascular and macrovascular complications, including retinopathy, nephropathy, neuropathy, cardiovascular disease (CVD), stroke, and peripheral arterial disease. For example, diabetic retinopathy is a leading cause of preventable blindness in adults, while diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) worldwide. Similarly, diabetic neuropathy increases the risk of foot ulcers and limb amputations. Collectively, these complications significantly reduce quality of life and contribute to increased morbidity and premature mortality among patients with diabetes (Kahn et al. 2019).

The epidemiological impact of T2DM is staggering. According to the International Diabetes Federation (IDF) Diabetes Atlas (10th edition, 2021), an estimated 537 million adults (20–79 years) were living with diabetes globally. This number is expected to rise dramatically, reaching 643 million by 2030 and 783 million by 2045, if current trends continue unchecked. More than three-quarters of people with diabetes reside in low- and middle-income countries, where

healthcare systems are often under-resourced and ill-equipped to manage the chronic nature of this disease. The rising incidence is closely linked to urbanization, aging populations, and widespread adoption of Western-style diets high in calories, sugar, and saturated fats. The global burden of T2DM is not limited to health outcomes—it also imposes a substantial economic cost. Direct costs include medical care, medication, diagnostic tests, and hospital admissions, while indirect costs encompass lost productivity, absenteeism, early retirement, and premature death (Salehi et al. 2019). The World Health Organization (WHO) estimates that the annual global health expenditure on diabetes exceeds USD 760 billion, making it one of the costliest chronic diseases to manage. The socio-economic burden is particularly severe in developing countries, where out-of-pocket expenses are high and access to healthcare is limited. Given the widespread prevalence and far-reaching consequences of T2DM, there is an urgent need for comprehensive strategies aimed at both prevention and management of the disease. Primary prevention focuses on lifestyle modifications—regular physical activity, a balanced and nutritious diet, weight management, and avoiding tobacco use and excessive alcohol consumption. Numerous studies have shown that even modest lifestyle interventions can significantly reduce the risk of developing T2DM in high-risk individuals, such as those with prediabetes or metabolic syndrome.

For individuals already diagnosed with T2DM, the goal of treatment is to achieve and maintain optimal glycemic control and prevent or delay the onset of complications. This often requires a combination of pharmacological therapy, dietary management, exercise, and patient education (Grover and Yadav 2002). Pharmacotherapy begins with oral hypoglycemic agents such as metformin, which remains the first-line drug due to its efficacy, safety profile, and cost-effectiveness. Depending on the patient's needs and disease progression, additional agents such as sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists may be introduced. In advanced stages, insulin therapy may become necessary. However, despite the availability of multiple therapeutic options, achieving long-term glycemic control remains challenging. Many patients experience treatment failure, side effects, or medication non-adherence. Moreover, most current therapies do not address the underlying causes of insulin resistance and beta-cell dysfunction (Tundis, et al. 2010). Therefore, ongoing research is focused on developing novel therapeutic agents and biological targets to improve patient outcomes. In addition to pharmacological innovation, there is a growing emphasis on the integration of digital health technologies, personalized medicine, and community-based interventions. Wearable devices, continuous glucose monitors (CGMs), and mobile

applications can empower patients to better manage their condition, while personalized treatment plans based on genetic and phenotypic profiles may optimize therapy. Furthermore, public health campaigns, diabetes screening programs, and early intervention initiatives can improve awareness and facilitate earlier diagnosis and treatment. In summary, Type 2 diabetes mellitus is not only a major global public health challenge but also a complex metabolic disease with multifaceted implications. Its increasing prevalence, associated complications, and economic burden highlight the urgent need for effective preventive strategies, innovative therapies, and comprehensive care models. A concerted effort involving healthcare providers, researchers, policymakers, and the public is essential to curb the diabetes epidemic and reduce its impact on future generations.

2. Pathophysiology of Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a complex metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin action, insulin secretion, or both. The pathogenesis involves intricate and interrelated contributions from genetic predisposition, epigenetic modifications, and environmental influences such as poor diet, sedentary lifestyle, and obesity. These factors act synergistically to impair glucose homeostasis through multiple mechanisms.

2.1 Insulin Resistance

One of the earliest abnormalities in T2DM is insulin resistance, which refers to the diminished capacity of insulin-responsive tissues—primarily skeletal muscle, liver, and adipose tissue—to respond to circulating insulin. As a result, glucose uptake by muscle is impaired, hepatic glucose production becomes unchecked, and lipolysis in adipose tissue increases. Insulin resistance is strongly linked to central (visceral) obesity, which leads to the secretion of adipokines and pro-inflammatory cytokines (e.g., TNF-α, IL-6) that interfere with insulin signaling pathways. Moreover, intracellular lipid accumulation in muscle and liver contributes to insulin desensitization through mechanisms such as serine phosphorylation of insulin receptor substrates (IRS) and mitochondrial dysfunction.

2.2 Beta-Cell Dysfunction

Initially, pancreatic beta-cells respond to insulin resistance by increasing insulin output—a state termed compensatory hyperinsulinemia. However, chronic overstimulation, combined

with glucotoxicity, lipotoxicity, oxidative stress, and islet inflammation, leads to progressive beta-cell dysfunction. This results in reduced insulin biosynthesis, impaired glucose-stimulated insulin secretion, and eventual beta-cell apoptosis. Genetic factors, such as polymorphisms in the TCF7L2 gene, also contribute to beta-cell susceptibility and impaired insulin gene transcription.

2.3 Hepatic Glucose Production

In healthy individuals, insulin suppresses hepatic gluconeogenesis and glycogenolysis. However, in T2DM, the liver continues to produce glucose inappropriately, especially during fasting periods. This is due to hepatic insulin resistance, which impairs insulin's ability to downregulate key gluconeogenic enzymes such as PEPCK and G6Pase. The resultant increase in hepatic glucose output contributes significantly to fasting and postprandial hyperglycemia.

2.4 Role of Incretins and Other Hormones

Incretins, particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), play an essential role in amplifying insulin secretion in response to oral glucose intake. In T2DM, this incretin effect is markedly reduced, due to both decreased hormone secretion and impaired responsiveness of beta-cells. Additionally, there is an inappropriate elevation of glucagon secretion from pancreatic alpha-cells, further worsening hyperglycemia by stimulating hepatic glucose production. Hormonal imbalances involving leptin, ghrelin, and adiponectin also disrupt glucose and lipid metabolism.

2.5 Oxidative Stress and Inflammation

Chronic low-grade inflammation and oxidative stress are central to the pathophysiology of T2DM. Excess nutrient intake and obesity generate reactive oxygen species (ROS) that damage cellular components and interfere with insulin signaling. Inflammatory mediators from adipose tissue macrophages and endothelial cells exacerbate insulin resistance and promote endothelial dysfunction. This inflammatory milieu fosters a self-perpetuating cycle of metabolic dysregulation, accelerating beta-cell demise and worsening insulin resistance.

3. Alpha-Glucosidase Inhibitors: Mechanism and Therapeutic Potential

Alpha-glucosidase inhibitors (AGIs) are a class of oral anti-diabetic drugs that target carbohydrate metabolism in the gastrointestinal tract. Alpha-glucosidase is a key enzyme located in the brush border of the small intestine that catalyzes the hydrolysis of

oligosaccharides and disaccharides into absorbable monosaccharides, such as glucose. By competitively inhibiting this enzyme, AGIs effectively delay carbohydrate digestion and subsequent glucose absorption (Karthikeyan et al. 2019). This mechanism blunts the postprandial (after-meal) rise in blood glucose, which is especially beneficial in patients with Type 2 Diabetes Mellitus (T2DM) who exhibit pronounced postprandial hyperglycemia. AGIs do not stimulate insulin secretion or improve insulin sensitivity; instead, they act locally in the gut, making their mechanism insulin-independent. As such, they are particularly useful in the early stages of diabetes or as adjunct therapy in combination with other antidiabetic agents.

3.1 Pharmacological Advantages

Alpha-glucosidase inhibitors offer several therapeutic advantages, particularly in managing postprandial glycemic excursions:

- **Effective Control of Postprandial Hyperglycemia**: AGIs such as acarbose, voglibose, and miglitol slow the conversion of dietary polysaccharides into glucose, reducing the glycemic load after meals. This helps in achieving tighter glycemic control and may improve overall glycemic variability.
- **Minimal Risk of Hypoglycemia**: Since AGIs do not increase insulin secretion or sensitivity, they do not pose a significant risk of hypoglycemia when used as monotherapy. This safety profile makes them suitable for elderly patients or those at risk of hypoglycemia from other antidiabetic agents.
- **Combination Therapy Compatibility**: AGIs can be effectively combined with other oral hypoglycemic agents or insulin. Their additive effects on lowering postprandial glucose levels complement the basal glycemic control offered by drugs like metformin, sulfonylureas, or DPP-4 inhibitors.
- **Weight Neutrality**: Unlike sulfonylureas or insulin, AGIs are generally weight-neutral and may even contribute to modest weight loss in some patients due to reduced calorie absorption and gastrointestinal side effects.
- **Cardiovascular Implications**: Some studies, including the STOP-NIDDM trial, have suggested that AGIs may offer cardiovascular benefits, such as reduced risk of myocardial infarction, by mitigating postprandial spikes in glucose and insulin—factors linked to atherosclerosis.

3.2 Limitations

Despite their advantages, AGIs are not without drawbacks, which may limit their widespread use:

- **Gastrointestinal Side Effects**: Common adverse effects include flatulence, bloating, abdominal discomfort, and diarrhea. These symptoms result from undigested carbohydrates being fermented by colonic bacteria. Though usually transient, they can be severe enough to affect patient adherence.
- **Dietary Restrictions**: The efficacy and tolerability of AGIs depend on dietary carbohydrate intake. Patients are often advised to follow specific dietary patterns, which may affect long-term compliance.
- **Modest Glycemic Efficacy**: Compared to other agents, AGIs produce only a modest reduction in HbA1c levels (typically 0.5% to 0.8%), making them less effective as monotherapy in advanced stages of T2DM.
- **Frequent Dosing Requirements**: AGIs need to be taken at the beginning of each main meal to be effective, which may be inconvenient for some patients and further affect adherence.

Despite these limitations, AGIs remain a valuable component of the therapeutic arsenal against T2DM, especially in populations consuming high-carbohydrate diets. They are particularly beneficial in Asian populations where rice and starch-rich meals are common. Moreover, their ability to modulate postprandial glucose excursions positions them as an important agent in comprehensive glycemic control strategies, especially in patients at risk for cardiovascular complications.

6. Future Directions and Challenges

The management of Type 2 Diabetes Mellitus (T2DM) is evolving rapidly, propelled by advances in biomedical research, pharmacological innovation, and digital technologies. Within this context, alpha-glucosidase inhibitors (AGIs) continue to play a critical role in attenuating postprandial hyperglycemia, a key contributor to the overall glycemic burden in T2DM patients. AGIs act by inhibiting carbohydrate digestion in the small intestine, thereby slowing glucose absorption and flattening post-meal blood glucose peaks. While their clinical efficacy has been well documented—particularly in populations with high-carbohydrate diets- there

remains considerable untapped potential for optimizing their use and effectiveness. Recent breakthroughs in molecular biology, computational drug discovery, and personalized medicine have opened new avenues for enhancing AGI therapy. These include the design of novel AGI analogues with improved selectivity and tolerability, the application of nanotechnology for targeted delivery, and the use of in silico models to predict drug performance and patient outcomes. Moreover, a deeper understanding of T2DM pathophysiology - especially the interplay between insulin resistance, gut microbiota, and metabolic inflammation - offers opportunities to refine the therapeutic application of AGIs in a more individualized and mechanistically informed manner. Consequently, the current landscape signals a shift from conventional, one-size-fits-all treatments toward more tailored and integrated strategies that combine pharmacological intervention with cutting-edge diagnostic and predictive tools. By harnessing these advancements, researchers and clinicians aim not only to improve the efficacy and safety of AGIs, but also to redefine their role in the broader framework of T2DM management.

6.1 Development of Dual or Multi-Target Agents

One promising avenue is the development of dual or multi-target AGIs—compounds capable of inhibiting more than one enzyme involved in glucose metabolism. By concurrently targeting enzymes such as alpha-amylase, DPP-4, or SGLT2 along with alpha-glucosidase, these agents may provide more comprehensive glycemic control. Such multitargeted therapies could reduce the need for polypharmacy and enhance patient adherence, while also potentially exerting synergistic effects on glucose regulation and metabolic health.

6.2 Minimization of Gastrointestinal Side Effects

The gastrointestinal side effects of AGIs remain a major barrier to their widespread acceptance. Current research is focused on developing novel formulations, such as prodrugs that are activated only at specific sites in the gastrointestinal tract, or encapsulation systems that allow targeted and sustained release. These strategies aim to localize the action of AGIs and minimize interactions with the gut microbiota, thereby reducing adverse effects like flatulence, bloating, and diarrhea.

6.3 Integration of Artificial Intelligence (AI) and Machine Learning (ML)

The integration of AI and ML into drug discovery pipelines has the potential to revolutionize AGI research. These technologies can rapidly analyze large datasets, predict pharmacokinetics

and toxicity, and optimize lead compounds through predictive modeling. AI-driven platforms can also simulate patient responses and forecast long-term outcomes, thus accelerating the transition from compound screening to clinical application. Additionally, AI can assist in patient stratification, enabling more precise and individualized treatment regimens.

6.4 Omics-Based Personalization

The application of omics technologies - genomics, proteomics, metabolomics, and transcriptomics - offers a new dimension in personalizing T2DM therapy. By integrating these datasets with computational biology tools, researchers can identify biomarkers that predict drug response, side effects, or disease progression. For AGIs, omics data can help tailor treatments to individuals based on genetic variations in carbohydrate metabolism or enzyme activity, potentially improving efficacy and minimizing side effects.

6.5 Bridging In Silico and In Vivo Translation

While in silico methods offer significant advantages in drug discovery, a persistent challenge lies in the accurate translation of computational predictions to biological systems. Many promising compounds identified through molecular docking or pharmacophore modeling fail to demonstrate efficacy in vitro or in vivo due to unanticipated metabolic instability, toxicity, or poor bioavailability. Bridging this gap requires more sophisticated in silico models that integrate dynamic physiological variables and iterative validation through experimental studies.

6.6 Regulatory and Commercialization Hurdles

The regulatory landscape for novel AGIs, especially those discovered via computational tools, poses its own set of challenges. Regulatory agencies require robust preclinical and clinical data to ensure safety and efficacy. Navigating these regulatory pathways demands significant investment and collaboration between academia, industry, and policymakers. Moreover, issues such as intellectual property rights, pricing strategies, and market accessibility must be addressed to ensure the successful commercialization of new therapeutic agents.

7. Conclusion

Type 2 Diabetes Mellitus represents a complex and multifaceted global health issue that necessitates innovative, patient-centered treatment strategies. Among the various therapeutic

classes, alpha-glucosidase inhibitors hold a unique position due to their ability to attenuate postprandial glucose excursions—an important aspect of overall glycemic control. Their localized mechanism of action and relatively low risk of hypoglycemia make them particularly suitable for specific dietary patterns and early intervention strategies. Recent advances in computational drug discovery, including molecular docking, pharmacophore modeling, and ADMET screening, have enabled the identification of novel AGI candidates with enhanced binding affinity and improved pharmacokinetic profiles. The integration of artificial intelligence and omics technologies further augments the potential for personalized and precision-based diabetes management. Nonetheless, considerable challenges remain. The gastrointestinal side effects associated with traditional AGIs, limited patient compliance, and the need for better predictive models of in vivo efficacy are ongoing barriers. Addressing these issues requires a synergistic approach that combines rational drug design, advanced in silico screening, experimental validation, and translational research. Looking ahead, the development of next-generation AGIs—characterized by greater potency, reduced side effects, and broader metabolic benefits—could significantly enhance the therapeutic armamentarium for T2DM. Through multidisciplinary collaboration and technological innovation, the future of AGI therapy holds promise for more effective and personalized diabetes care.

Table 1: Comparison of Major Antidiabetic Drug Classes

Drug Class	**Mechanism of Action**	**Example Drugs**	**Advantages**	**Limitations/Side Effects**
Biguanides	Inhibits hepatic glucose production; improves insulin sensitivity	Metformin	First-line therapy; low cost; weight neutral	GI distress; rare lactic acidosis
Sulfonylureas	Stimulates insulin secretion	Glimepiride, Glipizide	Rapid glucose lowering	Hypoglycemia; weight gain

Drug Class	Mechanism of Action	Example Drugs	Advantages	Limitations/Side Effects
	from pancreatic beta-cells			
Thiazolidinediones	Enhances insulin sensitivity via PPAR-γ activation	Pioglitazone, Rosiglitazone	Improves insulin resistance	Weight gain; fluid retention; fracture risk
DPP-4 Inhibitors	Inhibits degradation of incretins (GLP-1, GIP)	Sitagliptin, Saxagliptin	Weight neutral; low hypoglycemia risk	Modest HbA1c reduction; rare pancreatitis
GLP-1 Receptor Agonists	Mimics GLP-1 to enhance insulin secretion and reduce appetite	Liraglutide, Exenatide	Weight loss; cardiovascular benefits	GI side effects; injectable
SGLT2 Inhibitors	Promotes renal glucose excretion via SGLT2 inhibition	Dapagliflozin, Empagliflozin	Weight loss; cardiovascular and renal protection	Risk of UTI; dehydration; ketoacidosis
Alpha-Glucosidase Inhibitors	Delays carbohydrate digestion in intestine	Acarbose, Miglitol, Voglibose	Reduces postprandial glucose; minimal hypoglycemia	GI side effects; modest HbA1c effect

References-

1. American Diabetes Association. (2023). *Standards of medical care in diabetes—2023*. Diabetes Care, 46(Supplement_1), S1–S154. https://doi.org/10.2337/dc23-S001
2. DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*, 58(4), 773–795. https://doi.org/10.2337/db09-9028
3. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. *The Lancet*, 383(9922), 1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6
4. Grover, J. K., Yadav, S., & Vats, V. (2002). Medicinal plants of India with anti-diabetic potential. *Journal of Ethnopharmacology*, 81(1), 81–100.
5. Tundis, R., Loizzo, M. R., & Menichini, F. (2010). Natural products as alpha-amylase and alpha-glucosidase inhibitors. *Phytotherapy Research*, 24(3), 335–361.
6. Arumugam, N., Paal, M. C., & Mahalingam, P. (2013). Potential inhibitors of alpha-glucosidase for diabetes therapy. *Journal of Medicinal Chemistry*, 56(12), 4750–4763.
7. Kim, J. Y., Lee, H. J., & Cho, Y. S. (2019). Natural inhibitors of alpha-glucosidase and their therapeutic potential. *Biomedicine & Pharmacotherapy*, 120, 109558.
8. Salehi, B., Rescigno, A., & Sharifi-Rad, J. (2019). Medicinal plants with antidiabetic properties. *Molecules*, 24(6), 1235.
9. Vo, H. T., Choi, Y. H., & Kim, Y. S. (2016). Inhibitory effects of herbal extracts on alpha-glucosidase activity. *Fitoterapia*, 110, 129–136.
10. Shibano, M., Lin, A. S., & Fong, H. H. (2004). Inhibitory activity of flavonoids against alpha-glucosidase. *Journal of Natural Products*, 67(1), 118–120.
11. Cheng, F., Li, W., Zhou, Y., & Wang, Y. (2012). Molecular docking studies of alpha-glucosidase inhibitors. *Bioorganic & Medicinal Chemistry*, 20(24), 6950–6962.
12. Damian-Medina, L., Rivera-Toledo, E., & Pereda-Miranda, R. (2020). Structural insights into the inhibition of alpha-glucosidase. *Molecular Pharmacology*, 97(5), 452–462.
13. Ganesan, K., & Xu, B. (2017). Anti-diabetic effects of dietary polyphenols. *International Journal of Molecular Sciences*, 18(12), 2551.
14. Liu, Q., Zhang, H., & Wang, J. (2017). Advances in type 2 diabetes drug discovery. *Current Medicinal Chemistry*, 24(24), 2561–2575.

15. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. *Nature*, 414(6865), 813–820.
16. Nathan, D. M. (2015). Diabetes: Advances in diagnosis and treatment. *JAMA*, 314(10), 1052–1062.
17. Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., & Mendez, D. (2017). The ChEMBL database in 2017. *Nucleic Acids Research*, 45(D1), D945–D954.
18. Li, Y., Xu, S., & Zhang, Z. (2020). Pharmacokinetic properties of alpha-glucosidase inhibitors. *Drug Metabolism and Disposition*, 48(6), 498–507.
19. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Huerta-Cepas, J., & Morris, J. H. (2019). STRING v11: Protein-protein association networks. *Nucleic Acids Research*, 47(D1), D607–D613.
20. Patel, B. S., Kumar, R., & Sharma, P. (2012). Alpha-glucosidase inhibitors from natural sources. *Phytochemistry Reviews*, 11(2-3), 263–281.
21. Safitri, D., Tjandrawinata, R. R., & Hartono, P. (2020). Natural compounds as alpha-glucosidase inhibitors for diabetes therapy. *Journal of Ethnopharmacology*, 258, 112915.
22. Karthikeyan, A., & Rajkumar, M. (2016). In silico drug design for diabetes mellitus. *Computational Biology and Chemistry*, 60, 12–21.
23. Natarajan, R., & Deepa, M. (2018). Computational approaches for drug discovery in diabetes. *Trends in Pharmacological Sciences*, 39(12), 1095–1107.
24. Ponnusamy, S., & Kandaswamy, R. (2015). Molecular insights into diabetes drugs. *Current Drug Targets*, 16(7), 791–800.
25. Raskin, P., & Unger, R. H. (2010). Role of incretin hormones in diabetes therapy. *Diabetes Care*, 33(2), 372–379.